ScholarIQanswers from OpenAlex

Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea

PaperCitations, authors & open-access status

Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea have?

ScholarIQcitation count

Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea has 24 citations in the OpenAlex counts ScholarIQ stores.

When was Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea published?

ScholarIQyear

Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea has 2016 year in the ScholarIQ index.

What is the open-access status of Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea?

ScholarIQoa status

Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea has closed oa status in the ScholarIQ index.

What is the DOI of Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea?

ScholarIQdoi

The DOI for Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea is on the source record.

What is the PMID of Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea?

ScholarIQpmid

The PMID for Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea is on the source record.

What is the OpenAlex record for Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea?

ScholarIQopenalex

The OpenAlex for Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial